Clinical Trial Update: A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002) [Phase 1]

View source ↗

Summary

This trial update describes a Phase 1 study of VX-680 (MK-0457), an Aurora kinase inhibitor, in patients with advanced cancer, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• VX-680 (MK-0457)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cancer | Phase 1 | Status: TERMINATED